| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.11 | 0.001 |
| mRNA | SKI-II | CTRPv2 | pan-cancer | AAC | 0.12 | 0.001 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.17 | 0.003 |
| mRNA | AUY922 | GDSC1000 | pan-cancer | AAC | -0.1 | 0.003 |
| mRNA | BMS-536924 | GDSC1000 | pan-cancer | AAC | 0.094 | 0.003 |
| mRNA | Doxorubicin | GDSC1000 | pan-cancer | AAC | -0.1 | 0.004 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.1 | 0.004 |
| mRNA | MLN2238 | CTRPv2 | pan-cancer | AAC | 0.096 | 0.005 |
| mRNA | embelin | GDSC1000 | pan-cancer | AAC | -0.096 | 0.006 |